Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


BioXell Appoints Professor Peter van Brummelen to its Board of Directors


Professor Peter van Brummelen is currently an independent consultant to the pharmaceutical industry. As Executive Vice President of Research and Development at Yamanouchi Europe, from 1998 to 2003, he was responsible for the rapid and successful development of the new muscarinic antagonist, solifenacin, in overactive bladder as well as for the development of a new formulation of tamsulosin in benign prostatic hyperplasia. His previous positions include Vice President of Clinical Operations at Solvay Pharmaceuticals, Global Head of Clinical Pharmacology at Hoffmann-La Roche in Basel, and Professor of Medicine at the Universities of Leiden and Basel. Professor van Brummelen also serves as a Director on the Board of Basilea Pharmaceutica in Switzerland and of IQ Corporation in The Netherlands.

Professor van Brummelen stated: 'I am delighted to join the Board of Bioxell, a company recognised for its strong technology platform and promising development candidates”.

Francesco Sinigaglia, Chief Executive Officer of BioXell commented: “The addition of Peter reinforces the world-class leadership, in terms of both breadth and depth of experience, already evident in our Board. With the significant progress of 2004 behind us, we are now in a strong position to advance our lead compound, BXL628, in two Phase II trials, in two additional indications. The completion of a €23m financing in the fourth quarter of 2004 provides a strong cash position and underscores our ability to not only maintain, but also create new clinical momentum with BXL628”.


About BioXell
Spun-out from Roche in January 2002, BioXell is a private biopharmaceutical company focusing on the discovery and development of new treatments for urological disorders that represent large, currently underserved markets. Through its proprietary technology platform based on Vitamin D3 analogues, BioXell has identified a number of promising lead development programmes. Its pipeline includes BXL628 for benign prostatic hyperplasia and overactive bladder, currently in Phase II of clinical development, as well as compounds to treat other major urological indications such as interstitial cystitis and nonbacterial chronic prostatitis. In order to further exploit its Vitamin D3 platform, BioXell is collaborating with ProStrakan to develop drug candidates to cure osteoporosis and secondary hyperparathyroidism. Furthermore, based on its unique understanding of the inflammatory process and knowledge of GPCRs and TREM receptor biology, BioXell is also committed to a number of cutting-edge research projects to develop new drugs for chronic inflammatory diseases in collaboration with external partners. To date, BioXell has raised a total of over €70m through world-class specialised healthcare VC investors including MPM Capital, Index Ventures, AlpInvest Partners, BB BIOTECH and Life Science Partners as well as government funding. BioXell currently employs 60 people and has sites in Milan, Italy and Nutley, NJ, USA.

More information on BioXell can be found on: www.bioxell.com

Contact:

BioXell SpA
Alvise Sagramoso/Angela Evans
BioXell S.p.A
Via Olgettina 58
Milan
Italy
Tel: +39 (0)2 210 49 520
Fax: +39 (0)2 210 49 555
alvise.sagramoso@bioxell.com
angela.evans@bioxell.com

Financial Dynamics
Julia Phillips/Davina Langdale

Financial Dynamics
Holborn Gate
26 Southampton Buildings
London WC2A 1PB
United Kingdom
Tel: +44 (0)20 7269 7187
Fax: +44 (0)20 7242 8695
julia.phillips@fd.com


Publisher Contact Information:

Bioxell S.p.A.
+39 02-2104951
angela.evans@bioxell.com

Company profile of Bioxell S.p.A.
Past press releases of Bioxell S.p.A..

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.